APLLTD Alembic Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
Alembic Pharma delivered a strong Q2 FY26, characterized by robust double-digit growth in international markets and significant operating leverage. While the India business faced temporary GST-related disruptions, the US and ROW segments outperformed. Management is pivoting towards a higher-margin profile by targeting 20% EBITDA margins in the next two years and entering the US branded specialty space.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 13.7%, net profit up 7.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,580 | 1,406 | 1,571 | 1,494 | 1,796 +14% |
| EBITDA | 259 | 180 | 171 | 214 | 303 +17% |
| Net profit | 166 | 86 | 75 | 104 | 179 +8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
